Cero Therapeutics Holdings Inc. (Nasdaq: CERO) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation $(ODD)$ to its lead drug candidate, CER-1236, for the treatment of acute myeloid leukemia $(AML.AU)$. This designation highlights the significance of developing innovative treatments for conditions affecting fewer than 200,000 patients in the U.S. annually. CER-1236, currently in Phase 1 clinical trials, utilizes engineered T cell therapeutics that incorporate phagocytic mechanisms. The ODD status provides Cero with several incentives, including FDA assistance in trial design, access to the FDA Orphan Drug Grants Program, exemption from the drug approval application fee, and eligibility for seven years of marketing exclusivity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.